About This Guide

This guide provides supplemental clinical context for the Enbrel (etanercept) Dosing Calculator. It details the tool's outputs, instructions for use, and a summary of the dosing information used in its calculations. This content is intended for qualified healthcare professionals and students as an educational resource.

Outputs

The calculator provides a recommended subcutaneous dosing regimen based on the selected indication and required patient parameters. Key outputs include:

• Calculated Dose: The specific milligram (mg) amount per administration. For pediatric indications, this is a weight-based calculation (0.8 mg/kg) capped at the maximum adult dose.
• Dosing Frequency: How often the dose should be administered (e.g., once weekly).
• Dosing Phases: For adult plaque psoriasis, the tool provides separate dosing recommendations for the initial 3-month induction phase and the subsequent maintenance phase.
• Clinical Notes: Important context is provided where applicable, such as the maximum dose cap for pediatric patients or alternative approved dosing schedules for rheumatoid arthritis.

How to Use the Calculator

To operate the calculator and determine a dosing regimen, follow these steps:

• Select Indication: Choose the patient's condition from the dropdown menu (e.g., Rheumatoid Arthritis, JIA).
• Enter Patient Data: For pediatric indications (JIA and Pediatric Plaque Psoriasis), the tool requires the patient's age and weight to perform the calculation.
• Specify Weight Unit: Select whether the entered weight is in kilograms (kg) or pounds (lbs). The tool automatically converts lbs to kg for accuracy.
• Calculate: Click the "Calculate Dose" button to view the generated dosing recommendation.

Dosing Overview

The following regimens are based on the FDA-approved prescribing information for Enbrel:

• Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis (Adults): The standard dose is 50 mg once weekly. An alternative dose of 25 mg twice weekly is also approved for Rheumatoid Arthritis.
• Plaque Psoriasis (Adults): Includes an induction and maintenance phase.
  • Initial Dose (First 3 Months): 50 mg twice weekly.
  • Maintenance Dose (After 3 Months): 50 mg once weekly.
• Polyarticular Juvenile Idiopathic Arthritis (JIA; Ages 2+): The dose is 0.8 mg/kg once weekly, with a maximum dose not to exceed 50 mg.
• Plaque Psoriasis (Pediatric; Ages 4+): The dose is 0.8 mg/kg once weekly, with a maximum dose not to exceed 50 mg.

Switching Therapy

Switching a patient to Enbrel from another biologic or DMARD is a clinical decision that requires careful evaluation of the patient's history, disease activity, and reason for the switch (e.g., inadequate response, adverse event). A washout period may be necessary depending on the prior medication. All treatment changes must be made by the treating clinician.

Missed Dose

If a patient misses a dose of Enbrel, they should be instructed to administer the dose as soon as they remember and then resume their regular weekly dosing schedule. Patients should be advised not to take two doses at once to make up for the missed one and to contact their healthcare provider for specific guidance.

Safety Alerts (Boxed Warnings)

Enbrel has Boxed Warnings regarding serious health risks. Healthcare providers should be fully aware of these before initiating therapy.

• Serious Infections: Patients treated with Enbrel are at an increased risk for developing serious infections that may lead to hospitalization or death. These include tuberculosis (TB), bacterial sepsis, invasive fungal infections, and other opportunistic infections. Patients should be evaluated for TB risk factors and tested for latent infection prior to starting Enbrel.
• Malignancies: Lymphoma and other malignancies, some fatal, have been reported in children and adult patients treated with TNF blockers, including Enbrel.

This is not a complete list of risks. Please consult the full Prescribing Information for comprehensive safety data.

Frequently Asked Questions

1. Why does the calculator require age and weight for JIA and pediatric psoriasis?
Dosing for these pediatric indications is weight-based (0.8 mg/kg), so age and weight are essential for an accurate calculation.

2. What is the maximum calculated dose for a pediatric patient?
The calculator caps the pediatric dose at 50 mg per week, even if the weight-based calculation (0.8 mg/kg) exceeds this amount.

3. Why is there an "initial" and "maintenance" dose for adult plaque psoriasis?
The higher-frequency initial dosing (50 mg twice weekly) is used for the first 3 months to achieve rapid disease control. The frequency is then reduced to once weekly for long-term maintenance.

4. Can the 25 mg twice-weekly dose be used for psoriatic arthritis?
Based on the prescribing information used by this tool, the 25 mg twice-weekly alternative schedule is only specified for Rheumatoid Arthritis.

5. Does this tool account for co-morbidities like renal or hepatic impairment?
No. This tool provides standard dosing and does not adjust for organ impairment. Clinicians should consult the full prescribing information for guidance in these populations.

6. What Enbrel formulations are available in the U.S.?
Available formulations include 50 mg prefilled syringes and SureClick® autoinjectors, 25 mg prefilled syringes, and a 25 mg vial for reconstitution.

7. Why can't I find dosing for children with JIA under 2 years of age?
Enbrel is not approved by the FDA for use in JIA patients younger than 2 years of age.

8. Does this calculator provide dosing for off-label indications?
No, the calculator is strictly based on the FDA-approved prescribing information for the indications listed in the dropdown menu.

References

• Enbrel (etanercept) Prescribing Information. U.S. Food and Drug Administration.
• DailyMed - ENBREL (etanercept) injection, solution and kit. National Library of Medicine.
• Enbrel® (etanercept) | Official HCP Site. Amgen Inc.
• Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1-26.